Brief: Protara Therapeutics Gets FDA Breakthrough
05/01/2026 14:47
Jan 5 (Reuters) - Protara Therapeutics Inc TARA.O: PROTARA THERAPEUTICS RECEIVES BOTH FDA BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS FOR TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS Source text: ID:nGNX5Wqs5f Further company coverage: TARA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses